• Explore /
  • Poster
  • / Circulating tumor DNA (ctDNA) dynamics and survival outcomes in patients (pts) with advanced non-small cell lung cancer (aNSCLC) and high (>50%) programmed cell death-ligand 1 (PD-L1) expression, randomized to cemiplimab (cemi) vs chemotherapy (chemo).

Circulating tumor DNA (ctDNA) dynamics and survival outcomes in patients (pts) with advanced non-small cell lung cancer (aNSCLC) and high (>50%) programmed cell death-ligand 1 (PD-L1) expression, randomized to cemiplimab (cemi) vs chemotherapy (chemo).

Abstract Poster

Authors

null

Natalie I Vokes

Thoracic Head & Neck Medical Oncology, MD Anderson Cancer Center, Houston, TX

Natalie I Vokes , David R. Gandara , Ahmet Sezer , Saadettin Kilickap , Mahmut Gumus , Igor Bondarenko , Mustafa Özgüroğlu , Miranda Gogishvili , Haci M. Turk , Irfan Cicin , Dmitry Bentsion , Jinrui Liu , Nicholas Giangreco , Fang Wang , Siyu Li , Israel Lowy , Jean-Francois Pouliot , Giuseppe Gullo , Petra Rietschel , Vladimir Jankovic

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Lung Cancer—Non-Small Cell Metastatic

Track

Lung Cancer

Sub Track

Biologic Correlates

Clinical Trial Registration Number

NCT03088540

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 9022)

DOI

10.1200/JCO.2023.41.16_suppl.9022

Abstract #

9022

Poster Bd #

10

Abstract Disclosures

Similar Posters

First Author: Arielle Elkrief

First Author: Karen Kelly

First Author: Masayuki Shirasawa

First Author: Nashat Gabrail